Pancreatic Cancer Research

ResearcherSemmelweis UniversityActive in the last 2 years

Georg Beyer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7607-8264; OpenAlex author ID A5068096506. Sources: OpenAlex.

Their work

Papers
27 (first author 3, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
146
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 4 papers · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 5 papers · 2023: 3 papers · 2024: 3 papers · 2025: 3 papers · 2026: 1 paper

Papers 27

  1. Neutrophil-Driven Trogocytosis in Pancreatic Ductal Adenocarcinoma Liver Metastases Restrains Immunosuppressive Macrophage Polarization and Limits Metastatic P… Co-author DOI 10.1053/j.gastro.2026.04.021↗
  2. Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multic… Co-author DOI 10.1016/s2468-1253(25)00056-1↗
  3. Sustained Clinical Response to Olaparib in a Patient with Metastatic Pancreatic Cancer and Somatic ATM Mutation R2034Ter: A Case Report. Last author DOI 10.1159/000545975↗
  4. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  5. Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO … Co-author DOI 10.1007/s00432-024-05954-5↗
  6. Stereotactic body radiotherapy for pancreatic cancer - A systematic review of prospective data. Co-author DOI 10.1016/j.ctro.2024.100738↗
  7. Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response. Co-author DOI 10.1016/j.tranon.2024.102109↗
  8. [Pancreatic cancer-screening or surveillance?] Last author DOI 10.1007/s00117-023-01227-3↗
  9. Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. Co-author DOI 10.1007/s11523-023-00950-0↗
  10. Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achieving Excellent Response to Immunotherapy. Co-author DOI 10.1200/po.22.00650↗
  11. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  12. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancr… Co-author DOI 10.1053/j.gastro.2022.07.047↗
  13. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. Co-author DOI 10.1172/jci.insight.151353↗
  14. MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open rand… Last author DOI 10.1186/s13014-022-01988-6↗
  15. Role of stereotactic body radiation in the enhancement of the quality of life in locally advanced pancreatic adenocarcinoma: a systematic review. Last author DOI 10.1186/s13014-022-02076-5↗
  16. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenoc… Co-author DOI 10.1053/j.gastro.2021.05.055↗
  17. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  18. Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells10071821↗
  19. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkz060↗
  20. FAPα in pancreatic stellate cells upregulated by TGFβ1: a novel insight into pancreatic cancer progress. First author DOI 10.21037/atm-20-2559↗
  21. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. First author DOI 10.1016/j.pan.2018.10.003↗
  22. Plasma protein profiling of patients with intraductal papillary mucinous neoplasm of the pancreas as potential precursor lesions of pancreatic cancer. Co-author DOI 10.1016/j.cca.2017.12.008↗
  23. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2018.08.009↗
  24. [Pancreatic Cancer in the Year 2018 - Room for Precision Medicine?] First author DOI 10.1055/a-0542-4310↗
  25. [Chronic Pancreatitis and Pancreatic Cancer - Tumor Risk and Screening]. Co-author DOI 10.1055/s-0043-125407↗
  26. Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study. Last author DOI 10.1159/000453257↗
  27. New Advances in the Treatment of Metastatic Pancreatic Cancer. Co-author DOI 10.1159/000439523↗

Closest collaborators

The 25 strongest of 146 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Julia V. Mayerle · 18 shared papers, 2018–2026 · strength 2.33
  2. Marlies Vornhülz · 6 shared papers, 2022–2025 · strength 1.04
  3. Christoph Benedikt Westphalen · 5 shared papers, 2023–2025 · strength 0.85
  4. Steffen Ormanns · 6 shared papers, 2018–2026 · strength 0.74
  5. Ujjwal Mukund Mahajan · 7 shared papers, 2018–2022 · strength 0.66
  6. Volker Heinemann · 4 shared papers, 2020–2025 · strength 0.57
  7. Simon Sirtl · 3 shared papers, 2022–2025 · strength 0.55
  8. Frank Ulrich Weiß · 6 shared papers, 2018–2022 · strength 0.51
  9. Markus M. Lerch · 6 shared papers, 2018–2022 · strength 0.51
  10. Ivonne Regel · 5 shared papers, 2018–2022 · strength 0.51
  11. Kathrin Heinrich · 3 shared papers, 2023–2025 · strength 0.50
  12. Elisabetta Goni · 5 shared papers, 2018–2023 · strength 0.47
  13. Paul Rogowski · 2 shared papers, 2024–2025 · strength 0.41
  14. Kirsten Lauber · 3 shared papers, 2021–2026 · strength 0.40
  15. Yonggan Xue · 3 shared papers, 2020–2022 · strength 0.39
  16. John P. Neoptolemos · 4 shared papers, 2018–2024 · strength 0.38
  17. Jan Goesta D’Haese · 4 shared papers, 2018–2023 · strength 0.38
  18. Dieter Saur · 2 shared papers, 2022–2026 · strength 0.32
  19. Frederick Klauschen · 2 shared papers, 2023 · strength 0.29
  20. Klara Dorman · 2 shared papers, 2023–2024 · strength 0.28
  21. Roland Rad · 3 shared papers, 2018–2022 · strength 0.27
  22. Jens Werner · 3 shared papers, 2018–2023 · strength 0.26
  23. Stefan Hubert Boeck · 3 shared papers, 2018–2023 · strength 0.26
  24. Maximilian Reichert · 2 shared papers, 2022–2024 · strength 0.26
  25. William Greenhalf · 3 shared papers, 2018–2021 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.